Investors anticipate “bounce-back” in European private investment
The Swiss biotech ecosystem suffers from a “weak public market”, said Francesco de Rubertis, a cofounder at Medicxi Ventures. Despite…
The Swiss biotech ecosystem suffers from a “weak public market”, said Francesco de Rubertis, a cofounder at Medicxi Ventures. Despite…
Following 2023’s stiff economic environment, companies must prioritise partnerships more than ever in their growth strategies, said Richard Girling, a…
Smaller regulatory agencies could introduce more therapies into their national markets through faster regulatory processes, said Dr. Ulf Grawunder, managing…
As antibody-drug conjugates (ADCs) rise in popularity within the pharmaceutical sector, innovation may also soon follow, said Dr. Carl Deutsch,…
With the boom of cell and gene therapy development in recent decades, several regulators have scrambled to adapt their regulations…
Upcoming weekly insulin candidates can reduce the injection burden on patients with diabetes and ease the load on healthcare resources,…
Boehringer Ingelheim reported robust sales in 2023, with a 10.3% increase in human pharma sales that was strongly driven by…
A handful of UK charities and community pharmacists urged the UK government to find a fix for the ongoing drug…
Novartis declared plans to lay off approximately 680 staff members in its development organisation on 9 April. The workforce reductions…
Israeli cell technology company Pluri has expanded its cell-based product operations in a bid to support other companies with their…